Valuation: Compass Therapeutics, Inc.

Market Cap 367M 322M 299M 275M 517M 35.47B 526M 3.56B 1.39B 17.34B 1.38B 1.35B 59.92B P/E 2026 *
-4.68x
P/E 2027 * -4.39x
Enterprise Value 217M 191M 177M 163M 306M 20.99B 311M 2.11B 824M 10.26B 816M 798M 35.46B EV / Sales 2026 *
-106x
EV / Sales 2027 * 9.31x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-43.10%+32.67% - - 378M
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-0.54%+1.58%-15.68%-15.43% 23.35B
-1.82%-3.15%+3.76%+405.88% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.42%+24.22%+179.23% 14.11B
Average -4.34%-0.23%+44.55%+174.14% 26.56B
Weighted average by Cap. -0.24%-0.23%+44.16%+136.09%

Financials

2026 *2027 *
Net sales -2.06M -1.8M -1.68M -1.54M -2.9M -199M -2.94M -19.93M -7.8M -97.07M -7.72M -7.56M -336M 25.27M 22.15M 20.58M 18.9M 35.59M 2.44B 36.16M 245M 95.76M 1.19B 94.84M 92.81M 4.12B
Net income -82.44M -72.27M -67.15M -61.66M -116M -7.96B -118M -799M -312M -3.89B -309M -303M -13.45B -89.57M -78.52M -72.95M -67M -126M -8.65B -128M -868M -339M -4.23B -336M -329M -14.61B
Net Debt -150M -131M -122M -112M -211M -14.48B -215M -1.45B -568M -7.08B -563M -551M -24.47B -132M -116M -108M -98.74M -186M -12.75B -189M -1.28B -500M -6.23B -495M -485M -21.53B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.100USD
Average target price
8.500USD
Spread / Average Target
+304.76%

Quarterly revenue - Rate of surprise